BACKGROUND AND PURPOSE: The purpose of this study was to provide a simple and practical clinical classification for the etiology of intracerebral hemorrhage (ICH). METHODS: We performed a retrospective chart review of consecutive patients with ICH treated at the Helsinki University Central Hospital, January 2005 to March 2010 (n=1013). We classified ICH etiology by predefined criteria as structural vascular lesions (S), medication (M), amyloid angiopathy (A), systemic disease (S), hypertension (H), or undetermined (U). Clinical and radiological features and mortality by SMASH-U (Structural lesion, Medication, Amyloid angiopathy, Systemic/other disease, Hypertension, Undetermined) etiology were analyzed. RESULTS: Structural lesions, namely cavernomas and arteriovenous malformations, caused 5% of the ICH, anticoagulation 14%, and systemic disease 5% (23 liver cirrhosis, 8 thrombocytopenia, and 17 various rare conditions). Amyloid angiopathy (20%) and hypertensive angiopathy (35%) were common, but etiology remained undetermined in 21%. Interrater agreement in classifying cases was high (κ, 0.89; 95% CI, 0.82-0.96). Patients with structural lesions had the smallest hemorrhages (median volume, 2.8 mL) and best prognosis (3-month mortality 4%), whereas anticoagulation-related ICHs were largest (13.4 mL) and most often fatal (54%). Overall, median ICH survival was 5½ years, varying strongly by etiology (P<0.001). After adjustment for baseline characteristics, patients with structural lesions had the lowest 3-month mortality rates (OR, 0.06; 95% CI, 0.01-0.37) and those with anticoagulation (OR, 1.9; 1.0-3.6) or other systemic cause (OR, 4.0; 1.6-10.1) the highest. CONCLUSIONS: In our patients, performing the SMASH-U classification was feasible and interrater agreement excellent. A plausible etiology was determined in most patients but remained elusive in one in 5. In this series, SMASH-U based etiology was strongly associated with survival.
BACKGROUND AND PURPOSE: The purpose of this study was to provide a simple and practical clinical classification for the etiology of intracerebral hemorrhage (ICH). METHODS: We performed a retrospective chart review of consecutive patients with ICH treated at the Helsinki University Central Hospital, January 2005 to March 2010 (n=1013). We classified ICH etiology by predefined criteria as structural vascular lesions (S), medication (M), amyloid angiopathy (A), systemic disease (S), hypertension (H), or undetermined (U). Clinical and radiological features and mortality by SMASH-U (Structural lesion, Medication, Amyloid angiopathy, Systemic/other disease, Hypertension, Undetermined) etiology were analyzed. RESULTS:Structural lesions, namely cavernomas and arteriovenous malformations, caused 5% of the ICH, anticoagulation 14%, and systemic disease 5% (23 liver cirrhosis, 8 thrombocytopenia, and 17 various rare conditions). Amyloid angiopathy (20%) and hypertensive angiopathy (35%) were common, but etiology remained undetermined in 21%. Interrater agreement in classifying cases was high (κ, 0.89; 95% CI, 0.82-0.96). Patients with structural lesions had the smallest hemorrhages (median volume, 2.8 mL) and best prognosis (3-month mortality 4%), whereas anticoagulation-related ICHs were largest (13.4 mL) and most often fatal (54%). Overall, median ICH survival was 5&frac12; years, varying strongly by etiology (P<0.001). After adjustment for baseline characteristics, patients with structural lesions had the lowest 3-month mortality rates (OR, 0.06; 95% CI, 0.01-0.37) and those with anticoagulation (OR, 1.9; 1.0-3.6) or other systemic cause (OR, 4.0; 1.6-10.1) the highest. CONCLUSIONS: In our patients, performing the SMASH-U classification was feasible and interrater agreement excellent. A plausible etiology was determined in most patients but remained elusive in one in 5. In this series, SMASH-U based etiology was strongly associated with survival.
Authors: Fred Stephen Sarfo; Gloria Kyem; Bruce Ovbiagele; John Akassi; Osei Sarfo-Kantanka; Martin Agyei; Elizabeth Badu; Nathaniel Adusei Mensah Journal: J Stroke Cerebrovasc Dis Date: 2016-09-14 Impact factor: 2.136
Authors: Russell P Sawyer; Padmini Sekar; Jennifer Osborne; Steven J Kittner; Charles J Moomaw; Matthew L Flaherty; Carl D Langefeld; Christopher D Anderson; Jonathan Rosand; Daniel Woo Journal: Neurology Date: 2018-06-29 Impact factor: 9.910
Authors: Fred Stephen Sarfo; Ohene Opare-Sem; Martin Agyei; John Akassi; Dorcas Owusu; Mayowa Owolabi; Bruce Ovbiagele Journal: J Neurol Sci Date: 2018-09-20 Impact factor: 3.181
Authors: Jonathan Elmer; David Yamane; Peter C Hou; Susan R Wilcox; Ednan K Bajwa; Dean R Hess; Carlos A Camargo; Steven M Greenberg; Jonathan Rosand; Daniel J Pallin; Joshua N Goldstein; Sukhjit S Takhar Journal: Neurocrit Care Date: 2017-02 Impact factor: 3.210
Authors: David J Roh; David J Albers; Jessica Magid-Bernstein; Kevin Doyle; Eldad Hod; Andrew Eisenberger; Santosh Murthy; Jens Witsch; Soojin Park; Sachin Agarwal; E Sander Connolly; Mitchell S V Elkind; Jan Claassen Journal: Neurology Date: 2019-06-17 Impact factor: 9.910
Authors: David Roh; Chung-Huan Sun; J Michael Schmidt; Edip Gurol; Santosh Murthy; Soojin Park; Sachin Agarwal; E Sander Connolly; Jan Claassen Journal: Neurocrit Care Date: 2018-08 Impact factor: 3.210
Authors: Adnan I Qureshi; Mohammad R Afzal; Ahmed A Malik; Mushtaq H Qureshi; Nauman Jahangir; M Fareed K Suri Journal: J Vasc Interv Neurol Date: 2015-10